Stockscreener 앱 받기
9.40
1.47%
-0.14
시간 외 거래:
9.40
전일 마감가:
$9.54
열려 있는:
$9.56
하루 거래량:
1.01M
Relative Volume:
0.62
시가총액:
$834.48M
수익:
$71.64M
순이익/손실:
$-294.57M
주가수익비율:
-2.8076
EPS:
-3.348
순현금흐름:
$-84.46M
1주 성능:
+6.70%
1개월 성능:
+1.95%
6개월 성능:
-11.57%
1년 성능:
+44.84%
1일 변동 폭
$9.16
$9.605
1주일 범위
$8.51
$9.64
52주 변동 폭
$5.45
$12.49
Kura Oncology Inc Stock (KURA) Company Profile
명칭
Kura Oncology Inc
전화
(858) 500-8800
주소
4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA
Compare KURA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
9.40 | 846.91M | 71.64M | -294.57M | -84.46M | -3.348 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-14 | 개시 | Lake Street | Buy |
| 2025-09-04 | 개시 | Guggenheim | Neutral |
| 2025-02-06 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-10-14 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-12-22 | 개시 | Mizuho | Buy |
| 2023-08-11 | 개시 | BofA Securities | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Perform |
| 2023-05-17 | 개시 | BTIG Research | Buy |
| 2023-01-31 | 개시 | Stifel | Buy |
| 2022-07-12 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-02-15 | 개시 | Jefferies | Buy |
| 2021-05-05 | 재개 | Credit Suisse | Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-12-07 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-03 | 개시 | Stifel | Buy |
| 2020-11-05 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | 개시 | Credit Suisse | Outperform |
| 2020-05-05 | 개시 | Barclays | Overweight |
| 2019-07-18 | 개시 | Deutsche Bank | Buy |
| 2018-11-09 | 개시 | Piper Jaffray | Overweight |
| 2018-08-01 | 개시 | H.C. Wainwright | Buy |
| 2016-10-13 | 재개 | Leerink Partners | Outperform |
| 2016-01-22 | 개시 | JMP Securities | Mkt Outperform |
| 2015-12-30 | 개시 | Oppenheimer | Outperform |
| 2015-12-16 | 개시 | Citigroup | Buy |
모두보기
Kura Oncology Inc 주식(KURA)의 최신 뉴스
KURA Reiterates by Citizens -- Price Target Maintained at $24.00 - GuruFocus
Citizens reiterates Kura Oncology stock rating on strong trial data - Investing.com
Citizens reiterates Kura Oncology stock rating on strong trial data By Investing.com - Investing.com Canada
symbol__ Stock Quote Price and Forecast - CNN
Kura Oncology, Inc. (KURA) Presents at European Hematology Association (EHA) 2026 CongressSlideshow - Seeking Alpha
H.C. Wainwright Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $40 - Moomoo
KURA: Ziftomenib plus 7+3 shows high response and survival rates in AML, supporting phase III trials - TradingView
KURA: Ziftomenib plus 7+3 shows high, durable remission and survival in AML, supporting phase III trials - TradingView
Kura Oncology Inc EHA Investor Event Transcript - GuruFocus
Number of shareholders of Kura Oncology, Inc. – NASDAQ:KURA - TradingView
Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results For Ziftomenib And 7+3 Combination In Newly Diagnosed AML - marketscreener.com
Kura Oncology And Kyowa Kirin Report Encouraging Long-Term - GlobeNewswire
Kura Oncology Reports Inducement Grants under Nasdaq Listing Rule 5635(4) - marketscreener.com
Why Did KURA Stock Jump 13% In Pre-Market Today? - Stocktwits
The Technical Signals Behind (KURA) That Institutions Follow - Stock Traders Daily
How The Kura Oncology (KURA) Investment Narrative Is Evolving Without New Analyst Revisions - Yahoo Finance
Kura Oncology, Inc. (KURA) Discusses Clinical Data and Updated Development Strategy for DarlifarnibSlideshow - Seeking Alpha
A Quick Look at Today's Ratings for Kura Oncology(KURA.US), With a Forecast Between $23 to $40 - Moomoo
Kura Oncology Advances Targeted Combo in Tough Head and Neck Cancer - TipRanks
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Analysts’ Top Healthcare Picks: Kura Oncology (KURA), Align Tech (ALGN) - The Globe and Mail
UBS Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Director at Kura Oncology (NASDAQ: KURA) receives 35,000-share option grant - Stock Titan
Kura Oncology (KURA) director receives grant of 35,000 stock options at $8.77 - Stock Titan
Kura Oncology (KURA) awards director stock options at $8.77 strike - Stock Titan
Kura Oncology (KURA) director receives 35,000 options at $8.77 strike price - Stock Titan
Kura Oncology (KURA) director Carol Schafer granted 35,000 stock options - Stock Titan
Director Mary Szela awarded 35,000 Kura Oncology (KURA) options - Stock Titan
Kura Oncology (KURA) director receives option grant for 35,000 shares at $8.77 - Stock Titan
[8-K] Kura Oncology, Inc. Reports Material Event - Stock Titan
A Quick Look at Today's Ratings for Kura Oncology(KURA.US), With a Forecast Between $28 to $40 - Moomoo
Cantor Fitzgerald reiterates Kura Oncology stock Overweight rating By Investing.com - Investing.com South Africa
Cantor Fitzgerald reiterates Kura Oncology stock Overweight rating - Investing.com
Barclays Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Citizens reiterates Kura Oncology stock rating on FIT-001 data By Investing.com - Investing.com South Africa
Citizens reiterates Kura Oncology stock rating on FIT-001 data - Investing.com
Kura Oncology Inc ASCO Investor Event Transcript - GuruFocus
KURA Highlights Promising Data for Darlifarnib in KRAS-Mutant Ca - GuruFocus
Kura Oncology reports phase 1a data for cancer drug combination - Investing.com UK
Kura Oncology reports phase 1a data for cancer drug combination By Investing.com - Investing.com Australia
Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy - The Manila Times
Kura Oncology Reports Promising Phase 1a Results for Darlifarnib in Multiple KRAS-Mutant Cancers and Announces New Platform Study - Quiver Quantitative
Kura Oncology Highlights Darlifarnib’s Potential as a - GlobeNewswire
Kura Oncology Stock Hits Day Low of $9.03 Amid Price Pressure - Markets Mojo
Kura Oncology, Kyowa Kirin report trial results for AML drug By Investing.com - Investing.com South Africa
Kura Oncology, Kyowa Kirin report trial results for AML drug - Investing.com
Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML - The Manila Times
Blood journal reports 87% response with Kura AML drug combo - Stock Titan
KURA News | KURA ONCOLOGY INC (NASDAQ:KURA) - ChartMill
Kura Oncology Stock Hits Day Low of $10.39 Amid Price Pressure - Markets Mojo
Citizens reiterates Kura Oncology stock rating on FTI platform progress By Investing.com - Investing.com Australia
Kura Oncology Inc (KURA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.27%
1.43%
자본화:
|
볼륨(24시간):